First Spark Ventures, Llc — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration.
BiotechMedical DevicesBerkeley, US
Wesley Jackson(President, Chief Scientific Officer & Member of the Board)inGregory D. Kunst(Chief Executive Officer)Carole H Bellis(Executive Officer)Kevin E Healy(Director)Jackson M Wesley(Executive Officer, Director)
BoardDrew Lanza(Director)in
Co-investorsAngel Physicians FundBerkeley CatalystExSight VenturesPandect BioventuresExSight
Walking Fish Therapeutics develops cell therapies aimed at restoring health and function in patients.
AI & Machine LearningBiotechHealthtechMedical DevicesSouth San Francisco, US
Lewis Williams(Co-founder & CEO)inRusty Williams(Founder)Antonin de Fougerolles(Director)Momo Wu(Director)Stella Xu(Director)Alexis Ji(Director)
Co-investorsPandect BioventuresNorthpond Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.